Cart
sales@molnova.com
(S)-Enitociclib
CAS No. 1610408-97-3
(S)-Enitociclib( —— )
Catalog No. M36340 CAS No. 1610408-97-3
(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 715 | In Stock |
|
| 5MG | 1112 | In Stock |
|
| 10MG | 1359 | In Stock |
|
| 25MG | 1824 | In Stock |
|
| 50MG | 2213 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(S)-Enitociclib
-
NoteResearch use only, not for human use.
-
Brief Description(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
-
Description(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610408-97-3
-
Formula Weight404.43
-
Molecular FormulaC19H18F2N4O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOC1=C(C2=C(F)C=NC(NC3=CC(C[S@@](C)(=N)=O)=CC=N3)=C2)C=CC(F)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cdk2 Inhibitor II
Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.
-
AZD-5438
A potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively; also inhibits the kinase activity of p25-Cdk5 (IC50=14 nM) and GSK-3β (IC50=17 nM) in vitro.
-
AG-024322
AG-024322 is a potent ATP-competitive inhibitor targeting pan-CDK, effectively inhibiting cell cycle kinases CDK1, CDK2, and CDK4 with Ki values in the 1-3 nM range (1-3 nM).
